首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1348222篇
  免费   95795篇
  国内免费   2293篇
耳鼻咽喉   19077篇
儿科学   40429篇
妇产科学   36456篇
基础医学   210651篇
口腔科学   36879篇
临床医学   120377篇
内科学   250328篇
皮肤病学   28101篇
神经病学   100562篇
特种医学   53125篇
外国民族医学   221篇
外科学   207753篇
综合类   31336篇
现状与发展   4篇
一般理论   363篇
预防医学   102743篇
眼科学   31561篇
药学   102994篇
  1篇
中国医学   2659篇
肿瘤学   70690篇
  2018年   12640篇
  2015年   12593篇
  2014年   17572篇
  2013年   26481篇
  2012年   37073篇
  2011年   39917篇
  2010年   23084篇
  2009年   21169篇
  2008年   37145篇
  2007年   40771篇
  2006年   40095篇
  2005年   39205篇
  2004年   38418篇
  2003年   36960篇
  2002年   35636篇
  2001年   55770篇
  2000年   56960篇
  1999年   47812篇
  1998年   14006篇
  1997年   12497篇
  1996年   12449篇
  1995年   11714篇
  1994年   11044篇
  1992年   39608篇
  1991年   40568篇
  1990年   40179篇
  1989年   39039篇
  1988年   36264篇
  1987年   35939篇
  1986年   33867篇
  1985年   32770篇
  1984年   24993篇
  1983年   21318篇
  1982年   12700篇
  1981年   11699篇
  1980年   11028篇
  1979年   24961篇
  1978年   17982篇
  1977年   14890篇
  1976年   14443篇
  1975年   16324篇
  1974年   19569篇
  1973年   18810篇
  1972年   17743篇
  1971年   16603篇
  1970年   15764篇
  1969年   15034篇
  1968年   13767篇
  1967年   12568篇
  1966年   11370篇
排序方式: 共有10000条查询结果,搜索用时 281 毫秒
21.
Bulletin of Experimental Biology and Medicine - Ammonium, an end-product of catabolism, in low doses can promote adaptation of metabolic pathways in erythrocytes under conditions of extreme...  相似文献   
22.
23.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
24.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
25.
26.
27.
28.
29.
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号